Ascendis Pharma A (ASND) Other Operating Expenses (2018 - 2025)

Ascendis Pharma A has disclosed Other Operating Expenses across 8 years of filings, most recently posting $138.5 million for Q4 2025.

• Other Operating Expenses for Q4 2025 came in at $138.5 million, down 0.66% year-over-year; the trailing twelve-month figure through Mar 2026 was $138.5 million (down 0.66% YoY), and the FY2025 annual result was -$997.0 million, down 48.77% from the prior year.
• Other Operating Expenses came in at $138.5 million for Q4 2025 at Ascendis Pharma A, down from $139.5 million in the prior quarter.
• In the past five years, Other Operating Expenses ranged from a high of $139.5 million in Q4 2024 to a low of -$265.9 million in Q4 2022.
• The 5-year median for Other Operating Expenses is -$227.3 million (2023), against an average of -$95.6 million.
• Across the five-year window, Other Operating Expenses declined 1.14% in 2022 and surged 161.37% in 2024, its largest moves.
• Ascendis Pharma A's Other Operating Expenses stood at -$262.9 million in 2021, then retreated by 1.14% to -$265.9 million in 2022, then grew by 14.54% to -$227.3 million in 2023, then soared by 161.37% to $139.5 million in 2024, then decreased by 0.66% to $138.5 million in 2025.
• The last three Other Operating Expenses figures came in at $138.5 million (Q4 2025), $139.5 million (Q4 2024), and -$227.3 million (Q4 2023), per Business Quant data.